Abstract

STUDY DESIGN:PROSPECTIVE STUDY
PURPOSE:: TO EVALUATE THE EFFICACY OF DNTEK AS A TREATMENT MODALITY FOR AMBLYOPIA AND STRABISMUS
MATERIALS AND METHODS: 24 PATIENTS OF AMBLYOPIA , STRABISMUS AND NYSTAGMUS WERE ENROLLED.PATIENTS UNDERWENT AVERAGE 3-10 SESSIONS, EACH SESSION LASTING FOR MINIMUM 60 MINUTES.PATIENTS WERE EVALUATED FOR IMPROVEMENT IN VISION,STEREOPSIS,AMPLITUDE OF NYSTAGMUS AND AMOUNT OF STRABISMUS.CREATION OF FORMAT AND RETRIVAL OF DATA FROM EMR AND ANALYSED WITH SPSS 22.DESCRIPTIVE AND CROSS TABULATION USED FOR ANALYSES.P VALUE <0.05 CONSIDERED STASTICALLY SIGNIFICANT
RESULTS: FOLLOWING THERAPY, IMPROVEMENT IN VISUAL ACUITY(P=0.04),STEREOPSIS P=(0.04) AND AMOUNT OF STRABISMUS(P=0.04) WAS NOTED.THE STUDY IS CURRENTLY IN PROGRESS AND THE PATIENTS ARE FOLLOWED UP TO NOTE FOR ANY REGRESSION
CONCLUSION: DNTEK THERAPY IS SAFE,NONINVASIVE THERAPY FOR THE PATIENTS WITH AMBLYOPIA AND STRABISMUS